Executive leadership at Klotho Neurosciences.
Board of directors at Klotho Neurosciences.
Research analysts covering Klotho Neurosciences.
Recent press releases and 8-K filings for KLTO.
Klotho Neurosciences Announces Expiration of Letter of Intent
KLTO
M&A
New Projects/Investments
- Klotho Neurosciences announced that its Letter of Intent with Turn Biotechnologies was allowed to expire by both parties.
- The company's Board of Directors determined that the proposed transaction did not align with its long-term strategic plan.
- Klotho will now focus its resources on advancing its Klotho anti-aging protein research pipeline and developing treatments.
- The company highlights the longevity medicine market as a fast-growing sector, with the global aging population projected to reach 2.1 billion by 2050 and healthcare costs to exceed $47 trillion by 2030.
Oct 7, 2025, 10:20 PM
Klotho Neurosciences Signs LOI to Acquire Turn Biotechnologies Assets
KLTO
M&A
New Projects/Investments
- Klotho Neurosciences (KLTO) has signed a Letter of Intent (LOI) to acquire select assets from Turn Biotechnologies, including its ERA platform and eTurna RNA delivery system.
- The transaction includes a signed out-licensing and co-development partnership with a South Korean pharmaceutical company, valued at up to $300 million.
- This acquisition is intended to position Klotho as a leader in longevity therapeutics, expanding its mission and therapeutic reach, with plans for rebranding and integrating key Turn personnel.
Sep 30, 2025, 12:30 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more